Call for Abstract

5th International Conference on Preventive Oncology, will be organized around the theme “”

Preventive Oncology 2020 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Preventive Oncology 2020

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1
  • Track 1-2
  • Track 1-3
  • Track 2-1Lifestyle changes
  • Track 2-2Diet & Cancer
  • Track 2-3Vaccinations
  • Track 2-4Natural Therapy
  • Track 2-5Psychological & Social Aspects
  • Track 3-1Carcinogenesis
  • Track 3-2Molecular Targeted Therapies
  • Track 3-3Surgery and Laparoscopy
  • Track 3-4Hormone Replacement Therapy
  • Track 3-5Bone Marrow Transplantation
  • Track 3-6Chemotherapy
  • Track 3-7Cell, Molecular, and Stem Cell Biology
  • Track 3-8Genetics, Genomics, and Proteomics
  • Track 3-9Drug Discovery and Delivery
  • Track 3-10Clinical Research
  • Track 3-11Natural Therapy and Acupuncture
  • Track 4-1Oncogenes
  • Track 4-2Tumour Immunology
  • Track 4-3Tumour Biology
  • Track 4-4Tumour Progression
  • Track 4-5Carcinogenesis & Mutagenesis
  • Track 4-6Tumour Cell Interactions
  • Track 4-7Cancer Cell Pathology
  • Track 5-1Head & Neck Cancer
  • Track 5-2Thyroid Cancer
  • Track 5-3Pancreatic Cancer
  • Track 5-4Brain Cancer
  • Track 5-5Cervical Cancer
  • Track 5-6Prostate Cancer
  • Track 5-7Blood Cancer
  • Track 5-8Lung Cancer
  • Track 5-9Skin Cancer
  • Track 5-10Bone Cancer
  • Track 5-11Kidney Cancer
  • Track 6-1Metastatic Symptoms
  • Track 6-2Pathophysiology
  • Track 6-3Organ Specific Targets
  • Track 6-4Diagnosis & Management
  • Track 6-5Multimodal Therapies
  • Track 7-1Imaging Biomarker
  • Track 7-2Clinical Biomarkers
  • Track 7-3Genetic Biomarkers
  • Track 7-4Predictive Cancer Biomarkers
  • Track 7-5Molecular Biomarkers
  • Track 7-6Cell Free Biomarkers
  • Track 8-1Oncogenes
  • Track 8-2Proto-oncogenes
  • Track 8-3Cancer predisposition
  • Track 8-4Tumour Suppressors
  • Track 8-5Genetic Cancer Syndromes
  • Track 8-6Genetic Counselling & Testing
  • Track 9-1Sigmoidoscopy
  • Track 9-2Colonoscopy
  • Track 9-3Nuclear imaging
  • Track 9-4Screening test
  • Track 9-5Benefits of screening
  • Track 9-6Angiogenesis Inhibitors
  • Track 9-7Synthetic Lethality
  • Track 9-8Risks of screening
  • Track 9-9Molecular Diagnostics
  • Track 10-1Excisional biopsy
  • Track 10-2Incisional biopsy
  • Track 10-3Liquid biopsy
  • Track 10-4Stereotactic guided biopsy
  • Track 10-5Fine needle aspiration
  • Track 11-1Gene Therapy
  • Track 11-2Molecular Targeted Therapies
  • Track 11-3Hormone Replacement Therapy
  • Track 11-4Bone Marrow Transplantation
  • Track 11-5Chemotherapy
  • Track 11-6Radiation Therapy
  • Track 11-7Biomarkers in cancer detection
  • Track 11-8Immunotherapy
  • Track 12-1Therapeutic Monoclonal Antibodies
  • Track 12-2Small Molecule Drugs
  • Track 12-3Tyrosine kinase inhibitors
  • Track 12-4Hormone Therapies
  • Track 12-5Implications of Targeted Therapy
  • Track 12-6Targeted Cancer Therapy & Health Economics
  • Track 13-1Stem Cell Research
  • Track 13-2Cancer Stem Cells
  • Track 13-3Stem Cells and Tumours
  • Track 13-4Stem Cell Transplantation
  • Track 13-5Bone Marrow Transplantation
  • Track 13-6Cord Blood Stem Cells and Cancer
  • Track 14-1Localized cancer
  • Track 14-2Breast cancer
  • Track 14-3Metastatic cancer
  • Track 14-4Ovarian cancer
  • Track 14-5Prostate cancer
  • Track 15-1Trans anal Endoscopic Microsurgery
  • Track 15-2Robotic surgery
  • Track 15-3Reconstructive surgery
  • Track 15-4Laparoscopic cancer surgery
  • Track 15-5Cyto reductive surgery with HIPEC
  • Track 15-6Sarcoma surgery
  • Track 16-1 Cancer Specific Antigens
  • Track 16-2Tumour Immunogenicity
  • Track 16-3Antitumor Immune Response
  • Track 16-4Tumour Elimination`
  • Track 16-5Cancer Immuno surveillance
  • Track 16-6Cancer Immunology and Chemotherapy
  • Track 16-7 Cancer & Viruses
  • Track 17-1 Tumour Targeting Strategies
  • Track 17-2 Hormonal & Biological Agents
  • Track 17-3 Cancer Drug Targets
  • Track 17-4 Clinical Trials
  • Track 17-5 Anticancer Therapeutics
  • Track 17-6Preclinical Models for Drug Evaluation
  • Track 17-7 Research and Analytical Methods
  • Track 18-1 Gerson therapy
  • Track 18-2Acupuncture
  • Track 18-3Integrative Medicine
  • Track 18-4Dietary Supplements and Herbal Remedies
  • Track 18-5Biologic Treatments
  • Track 18-6Meditation & Yoga
  • Track 19-1Tumour cell proliferation
  • Track 19-2Genomic Studies
  • Track 19-3Cancer Genome Atlas(TCGA)
  • Track 19-4Genomics Tools
  • Track 19-5Metabolite Pathways
  • Track 19-6Metabolic Technologies
  • Track 19-7Data Interpretations
  • Track 19-8Metabolomics as Biomarker
  • Track 20-1Viral Mimicry of genes
  • Track 20-2Principle investigator
  • Track 20-3 Viral Therapy
  • Track 20-4 Viral associated Cancers
  • Track 21-1Nanoparticle packages
  • Track 21-2Energy absorption and radiation
  • Track 21-3Laser ablation
  • Track 21-4Active pharmaceutical ingredients
  • Track 21-5Passive Tumor Accumulation
  • Track 21-6Active Tumor Targeting
  • Track 22-1Nursing Education
  • Track 22-2Nursing Management
  • Track 22-3Nursing Law
  • Track 22-4Clinical Nursing
  • Track 22-5Critical Care
  • Track 22-6Continuing Nursing Education
  • Track 23-1Cancer Epigenetics
  • Track 23-2Molecular Profiling Techniques
  • Track 23-3New Biologics & Vaccines
  • Track 23-4Chemical Proteomics
  • Track 23-5Combination Strategies in Immuno oncology
  • Track 23-6Novel Biomarker Discovery
  • Track 24-1Alcohol and Tobacco
  • Track 24-2Diet and Obesity
  • Track 24-3Environmental pollutants
  • Track 24-4 Radiation
  • Track 24-5Magnetic Resonance Imaging
  • Track 24-6Endoscopic Ultrasound
  • Track 24-7Tumor Molecular Profiling
  • Track 24-8 X-ray
  • Track 24-9Nuclear Medicine Imaging
  • Track 25-1Unexpected/Unusual Conditions
  • Track 25-2Rare Surgical Condition of a cancer case
  • Track 25-3Novel Surgical Procedure
  • Track 25-4Adverse Effects